Skip to content

CorMedix CRMD Amortization Of Intangibles

Amortization Of Intangibles at other companies

Fortune Brands Innovations logo
Fortune Brands InnovationsFBIN
$18.6M+3.3%
PDF Solutions logo
PDF SolutionsPDFS
$2.06M+94.8%
Catalyst Pharmaceutical logo
Catalyst PharmaceuticalCPRX
$9.7M+3.8%
John Wiley & Sons, Inc. logo
John Wiley & Sons, Inc.WLYB
$13.25M+2.7%
Bausch Health Companies logo
Bausch Health CompaniesBHC
$241M-5.9%
Sotera Health logo
Sotera HealthSHC
$3.03M-80.2%

Other financials

Income statement

See full
Revenue$127.4M+226%
Gross profit$115.4M+207%
Operating income$63.7M+216%
Net income$38.6M+87.0%
EPS (diluted)$0.43+43.3%

Balance sheet

See full
Cash & equivalents$179.1M+170%
Total debt$4.3M+729%
Total equity$437.0M+280%
Total assets$815.6M+445%

Cash flow

See full
Operating cash flow$42.4M+115%
CapEx$729.0K+7,190%
Free cash flow$41.7M+111%

Valuation

See full
Market cap$605.65M-34.4%
P/E3.4×
P/S1.5×-9.6×

Profitability

See full
Gross margin91.9%-3.5pp
Operating margin48.4%
Net margin45.2%
FCF margin48.7%+38.8pp

Returns & leverage

See full
Return on equity65.6%
Debt / equity0.0×
Current ratio-1.2×

Where this comes from

Reported directly by CorMedix in its filing.

Tagged under the XBRL concept crmd:AmortizationOfIntangibles.

The official record: CorMedix’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about CorMedix's amortization of intangibles.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is CorMedix's amortization of intangibles?
CorMedix (CRMD) reported amortization of intangibles of $10.3M in Q1 2026.
How has CorMedix's amortization of intangibles changed year-over-year?
CorMedix's amortization of intangibles increased by 19707.7% year-over-year, from $52K to $10.3M.
What does amortization of intangibles mean?
Represents the periodic expense recognized to allocate the cost of acquired intangible assets, such as patents or licenses, over their estimated useful lives. This non-cash charge reflects the gradual consumption of the economic value of intellectual property essential to the company's product portfolio.